Alpha Cognition Inc. Common Stock
- Open
- 9.20
- Day high
- 9.37
- Day low
- 9.01
- Prev close
- 9.16
- Volume
- 215K
- Mkt cap
- $202M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 3.8
- P/S
- 13.2
- Yield
- —
- Per share
- —
- ▲Insiders net buying $3.4M over the last 3 months (15 open-market buys, 0 sales)
- 🏛Institutions reducing (13F)
Alpha Cognition Inc. Common Stock (ACOG) is a Financial Services company listed on NASDAQ. The stock is up 12% over the past year. Over the trailing 3 months, insiders filed 15 open-market buys and 0 sales (SEC Form 4).
Alpha Cognition Inc. Common Stock (ACOG) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 3 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ACOG earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 13, 2026 | $-0.39 | $-0.40 | -2.0% | $6M | +36.9% |
| May 14, 2026 | $-0.41 | $-0.37 | +9.8% | $4M | +3.2% |
| Mar 26, 2026 | $-0.27 | $-0.30 | -11.1% | $3M | -18.8% |
| Nov 13, 2025 | $-0.43 | $-0.30 | +30.2% | $3M | -46.0% |
| Aug 14, 2025 | $-0.46 | $-0.65 | -41.3% | $2M | -60.1% |
| May 15, 2025 | $-0.58 | $-0.20 | +65.5% | $3M | +485.7% |
| Mar 31, 2025 | $-0.48 | $-0.51 | -6.3% | — | — |
| Nov 14, 2024 | $-1.00 | $-0.31 | +69.0% | — | — |
| Mar 31, 2024 | — | $-0.87 | — | — | — |
| Dec 31, 2023 | — | $-1.55 | — | — | — |
| Sep 30, 2023 | — | $-0.84 | — | — | — |
| Jun 30, 2023 | — | $-0.74 | — | — | — |
ACOG insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 24, 2026 | Wills Robert Jamesdirector | Buy | 10,000 | $9.62 |
| Aug 4, 2026 | Opaleye Management Inc.10 percent owner | Buy | 50,000 | $8.00 |
| Aug 4, 2026 | Opaleye Management Inc.10 percent owner | Buy | 2,900 | $7.92 |
| Jul 28, 2026 | Opaleye Management Inc.10 percent owner | Buy | 130 | $7.90 |
| Jul 24, 2026 | Opaleye Management Inc.10 percent owner | Buy | 140,237 | $7.83 |
| Jul 24, 2026 | Opaleye Management Inc.10 percent owner | Buy | 49,849 | $7.80 |
| Jul 24, 2026 | Opaleye Management Inc.10 percent owner | Buy | 10,000 | $7.83 |
| Jun 29, 2026 | Opaleye Management Inc.10 percent owner | Buy | 152,336 | $6.40 |
| Jun 29, 2026 | Opaleye Management Inc.10 percent owner | Buy | 197 | $6.50 |
| Jun 15, 2026 | Opaleye Management Inc.10 percent owner | Buy | 273 | $5.93 |
| Jun 15, 2026 | Opaleye Management Inc.10 percent owner | Buy | 4,550 | $5.99 |
| Jun 15, 2026 | Opaleye Management Inc.10 percent owner | Buy | 2,862 | $5.91 |
| Jun 11, 2026 | Opaleye Management Inc.10 percent owner | Buy | 24,856 | $5.98 |
| Jun 11, 2026 | Opaleye Management Inc.10 percent owner | Buy | 5,872 | $5.99 |
| Jun 9, 2026 | Opaleye Management Inc.10 percent owner | Buy | 10,054 | $5.83 |
Source: ACOG SEC Form 4 filings, latest Aug 24, 2026. For informational purposes only — not investment advice.
See the full ACOG insider & 13F page →Alpha Cognition Inc. Common Stock company profile
Overview
Alpha Cognition Inc. (NASDAQ:ACOG) is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Vancouver, Canada. The company was formerly known as Crystal Bridge Enterprises Inc. before changing its name in March 2021. Alpha Cognition focuses on developing treatments for neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company successfully transitioned from a pre-revenue clinical-stage entity to a commercial-stage company in 2025 with the launch of its flagship product ZUNVEYL for treating mild-to-moderate Alzheimer's disease.
Business
Alpha Cognition operates in the biopharmaceutical industry, specifically focusing on neurodegenerative diseases that affect millions of people worldwide. The company's primary focus is on Alzheimer's disease, a progressive brain disorder that causes memory loss, cognitive decline, and behavioral changes, affecting over 6 million Americans. The company also develops treatments for amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, which is a fatal neurodegenerative disease that affects nerve cells controlling voluntary muscles. The company's core commercial product is ZUNVEYL (benzgalantamine), which received regulatory approval for treating mild-to-moderate Alzheimer's disease and mild traumatic brain injury. ZUNVEYL is an enhanced version of galantamine, a medication that works by inhibiting acetylcholinesterase, an enzyme that breaks down acetylcholine in the brain. Acetylcholine is a neurotransmitter crucial for memory and learning functions. By preventing its breakdown, ZUNVEYL helps maintain cognitive function in Alzheimer's patients. The drug is specifically formulated to potentially reduce gastrointestinal side effects commonly associated with traditional galantamine treatments. Beyond its commercial product, Alpha Cognition maintains a development pipeline including ALPHA-0602, a gene therapy approach for ALS treatment, and ALPHA-0702 and ALPHA-0802, which are granulin epithelin motifs designed to treat various neurodegenerative diseases. The company generates revenue primarily from ZUNVEYL product sales, which began in March 2025, and licensing agreements for international territories.
Competitive moat
Alpha Cognition's competitive moat is relatively narrow, typical of specialty pharmaceutical companies with single-product focus. The company's primary defensive position stems from its patent protection, with ZUNVEYL protected through 2044 following a recent composition of matter patent approval. This provides approximately two decades of exclusivity for the specific formulation. The company also benefits from regulatory barriers, as competitors would need to conduct extensive clinical trials and obtain FDA approval to launch competing products. However, Alpha Cognition faces significant competitive threats that limit its moat strength. The Alzheimer's treatment market includes established players like Eisai/Biogen with Leqembi, Roche with gantenerumab, and traditional treatments like Aricept (donepezil). These competitors possess substantially larger resources, established physician relationships, and comprehensive disease management programs. The company's limited scale compared to major pharmaceutical companies restricts its ability to invest in extensive clinical programs or marketing initiatives. The most significant vulnerability is the company's single-product dependence on ZUNVEYL, creating concentration risk. While the pipeline includes gene therapy and other approaches, these remain in early development stages. Additionally, the fundamental challenge of treating Alzheimer's disease means that breakthrough therapies from larger competitors could significantly erode ZUNVEYL's market position. The company's moat is therefore best characterized as moderate and time-limited, dependent on successful execution during the patent protection period and pipeline advancement to sustain long-term competitive advantages.
Risks & safety
Alpha Cognition demonstrates a strong near-term financial safety profile but faces longer-term sustainability challenges. • Liquidity position: Excellent with $45.5 million cash and short-term investments as of Q1 2025, providing substantial runway • Debt structure: Essentially debt-free with debt-to-equity ratio of 0.0, eliminating financial leverage risk • Current operations: Strong current ratio of 17.14x indicates excellent short-term liquidity management • Cash burn: Operating cash flow negative $2.0 million in Q1 2025, with management projecting $38-42 million annual expenses for 2025 • Revenue trajectory: Early commercialization showing promise with $347k in initial ZUNVEYL sales and $1 million through April 2025 • Valuation concerns: Trading at significant premium with negative EBITDA, though Graham net-net ratio of 2.40 suggests asset backing • Break-even timeline: Management targets cash flow positive by year three of launch (approximately 2028) • Key risk: Single-product dependence creates binary outcome risk if ZUNVEYL commercialization fails to meet expectations
Recent development
Alpha Cognition has undergone significant strategic transformation over the past two years, transitioning from a pre-revenue clinical-stage company to a commercial-stage biopharmaceutical enterprise. The most significant milestone was the successful launch of ZUNVEYL in March 2025, marking the company's entry into revenue generation after years of development. The commercial launch strategy focused on the long-term care market, with the company assembling an experienced sales team averaging 16 years of industry experience. The company executed a major capital raising initiative through its NASDAQ listing, securing $52 million in gross proceeds to fund commercialization efforts. This funding provided the financial foundation for the commercial launch and ongoing operations. Concurrently, Alpha Cognition established its first international partnership with CMS Pharmaceuticals, granting exclusive rights for China and Asian territories, which generated $2.6 million in licensing revenue and demonstrates the global potential for ZUNVEYL. Strategic pipeline developments include reclaiming two development programs from Alpha Seven Therapeutics and initiating sublingual formulation work on ALPHA-1062. The company secured additional patent protection extending ZUNVEYL's exclusivity through 2044, strengthening its competitive position. Management has indicated plans for additional international partnerships in late 2025, suggesting continued geographic expansion. The company's focus has clearly shifted from pure research and development to commercial execution while maintaining pipeline advancement, positioning it for sustainable growth beyond its initial product launch.
ACOG company profile · for informational purposes only — not investment advice.
Track ACOG with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free